InfuSystem Holdings Inc.
03/19/2026 | Press release | Distributed by Public on 03/19/2026 06:46
Change in Certifying Accountants (Form 8-K)
Item 4.01 - Changes in Registrant's Certifying Accountant
The Audit Committee (the "Committee") of the Board of Directors of InfuSystem Holdings, Inc. (the "Company") conducted a competitive selection process to determine the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The Committee invited several firms to participate in this process, including Deloitte & Touche LLP ("Deloitte"), the Company's independent registered public accounting firm for the year ended December 31, 2025.
As a result of this process, following the review and evaluation of proposals from participating firms, on March 13, 2026, the Committee approved the dismissal of Deloitte as the Company's independent registered public accounting firm and the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to audit the Company's consolidated financial statements as of and for the fiscal year ending December 31, 2026, and to review the Company's quarterly consolidated financial statements for each of the first three quarters of the fiscal year ending December 31, 2026, and to audit the Company's internal control over financial reporting as of December 31, 2026.
During the fiscal years ended December 31, 2025 and 2024, and the subsequent interim period through March 13, 2026, neither the Company nor anyone on its behalf consulted with Grant Thornton regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that Grant Thornton concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).
The audit reports of Deloitte on the consolidated financial statements of the Company for the fiscal years ended December 31, 2025 and 2024 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.
During the fiscal years ended December 31, 2025 and 2024, and the subsequent interim period through March 13, 2026, there were no disagreements with Deloitte on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte, would have caused Deloitte to make reference to the subject matter of such disagreements in connection with its reports on the consolidated financial statements for such fiscal years. During the fiscal years ended December 31, 2025 and 2024, and the subsequent interim period through March 13, 2026, there have been no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K).
The Company provided Deloitte with a copy of the disclosures in this Current Report on Form 8-K and requested that Deloitte furnish to the Company a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of Deloitte's letter dated March 19, 2026 is attached hereto as Exhibit 16.1.
InfuSystem Holdings Inc. published this content on March 19, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 19, 2026 at 12:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]